#USA #New York #Gross Law Firm #Aquestive Therapeutics #AQST

Shareholder Alert: Join the Class Action Against Aquestive Therapeutics

On March 24, 2026, The Gross Law Firm released an important notice urging shareholders of Aquestive Therapeutics, Inc. (NASDAQ: AQST) to consider joining a class action lawsuit related to the recent issues surrounding the company’s new drug application. Many investors who purchased shares during the class period from June 16, 2025, to January 8, 2026, may be eligible for participation in this legal action.

Background of the Case

The class action lawsuit emerges amid allegations that the company misled investors regarding its new drug, Anaphylm (Dibutepinephrine) sublingual film. According to the complaint, the defendants are accused of providing overly optimistic statements about the drug’s approval process while simultaneously concealing significant negative information. Specifically, it is claimed that the company downplayed critical human factors associated with the use of Anaphylm, such as its packaging, administration, and labeling.

On January 9, 2026, Aquestive disclosed receiving a letter from the FDA that highlighted deficiencies in their drug application. This letter indicated that discussions about labeling for Anaphylm could not proceed until these issues were resolved. Moreover, the FDA confirmed that the review process for the drug application was ongoing, and a final decision was yet to be made. This announcement resulted in a severe decline in Aquestive’s stock price, dropping from $6.21 per share on January 8 to $3.91 on January 9—an astonishing decrease of over 37% in just one day.

Importance of Acting Quickly

Shareholders are strongly encouraged not to delay in registering for this class action. The deadline for investors wishing to seek a lead plaintiff status is May 4, 2026. Participating in this case at this stage does not require a commitment to bring legal action, allowing shareholders to maintain the right to recover losses without the complexities of a lead plaintiff role. Those interested can register their information through the provided link to receive case updates and monitor the situation throughout its course.

The Role of The Gross Law Firm

The Gross Law Firm is a nationally recognized entity specializing in class action lawsuits. They are dedicated to representing individuals who have suffered financial losses due to deceptive practices or false statements made by companies. The firm insists on holding corporations accountable for their actions and is aggressively pursuing recovery for those impacted by the alleged misrepresentation of Aquestive’s business practices.

By joining forces with The Gross Law Firm, shareholders can take a stand against potential misconduct in the business environment. The firm states that prior outcomes do not guarantee similar results, but their commitment to investor protection remains steadfast.

Call to Action

If you have suffered losses due to investments in Aquestive Therapeutics during the specified class period, contacting The Gross Law Firm is a crucial step. Register now to ensure you are equipped with all the necessary information and updates regarding the ongoing lawsuit. This is your opportunity to stand up and seek justice as part of a larger group of investors who have faced similar adversity.

For further inquiries or to register your information, please reach out to The Gross Law Firm at their New York office, via email, or on their direct phone line. Act quickly to secure your rights as an investor and remain informed throughout this vital legal process.

Contact Information

• - The Gross Law Firm

15 West 38th Street, 12th Floor
New York, NY, 10018
Email: [email protected]
Phone: (646) 453-8903

Being vigilant and taking prompt action is essential for all shareholders looking to recover their losses. Don't miss out on this critical opportunity.